This issue of Molecular Imaging Insight focuses on test accuracy, cost and outcomes—all very key topics in 2012.

The image of the lone physician “listening for zebras” as he combs through a mental library of diagnoses is fast becoming a thing of the past. Some answers are objectively better than others, so the only real question is how to conveniently get those answers.

Positron's subsidiary, Manhattan Isotope Technology, has received an acknowledgment letter and Drug Master File number assignment from the FDA for its strontium-82 drug substance.

Breast-specific y camera scintigraphy is a highly specific tool for ductal carcinoma in situ (DCIS) detection, and provides 100 percent sensitivity when paired with mammography, according to a study published in the October issue of the Journal of Nuclear Medicine.

The FDA has approved the first ultrasound device for use in combination with a standard mammography in women with dense breast tissue who have a negative mammogram and no symptoms of breast cancer.

California Gov. Jerry Brown has signed a bill requiring physicians to give extra warnings to women with dense breast tissue, informing the women that additional screening through ultrasound or MRI, as opposed to mammography alone, may be recommended.

Use of PET among Medicare beneficiaries with cancer increased from 2004 to 2008, but the increase was not even between sociodemographic groups as the modality had higher utilization among whites and those in higher income zip codes, according to a study published in the September issue of Journal of the American College of Radiology.

As radiology equipment becomes ever more advanced, so-called “structured data” only increases. Advanced 3D and reconstruction visualization generates measurements from multiple angles, and the digital information builds and builds.